Newamsterdam Pharma CO NV Schedule 13D activist filings

Bain Capital Life Sciences entities have sold a significant portion of their holdings in NewAmsterdam Pharma, dropping their beneficial ownership below the 5% reporting threshold.

Bain Capital Life Sciences entities sold 4.8 million NewAmsterdam Pharma shares for $168.4 million, reducing their collective beneficial ownership to approximately 6.4%.

Bain Capital entities filed an amended Schedule 13D for NewAmsterdam Pharma, maintaining a 9.99% beneficial ownership stake, while Nicholas Downing resigned from the board.

Frazier Life Sciences Public Fund increases its stake in NewAmsterdam Pharma Company N.V. following a merger with Frazier Life Sciences Public Overage Fund.

Forbion Capital Partners and related entities have filed an amendment to their beneficial ownership in NewAmsterdam Pharma Company N.V., reporting an aggregate stake of 8.3%.

Frazier Life Sciences funds have updated their beneficial ownership in NewAmsterdam Pharma, detailing recent share purchases and clarifying ownership attribution.

Forbion Capital Partners and related entities updated their beneficial ownership in NewAmsterdam Pharma Company N.V., collectively holding 9.4% of outstanding shares.